RxDoctor Payments Data

Marc Janis, MD

Urology · Mount Vernon, NYNPI 1669587879

Payments from drug & device makers

$13,374in general payments, 2019–2025

Across 508 payments — averaging $26.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Sumitomo Pharma America, Inc.$2K
  • Astellas Pharma US Inc$1K
  • Coloplast$628
  • Pfizer$603
  • Myriad Genetic Laboratories, Inc.$559
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$1001%
  • Travel & lodging$2402%
  • Food & beverage$12,18891%
  • Education$8466%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,374 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$538,425
Medicare patients
622
Services billed
85,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide59$1,178,334
XtandiEnzalutamide43$590,920
GemtesaVibegron455$331,791
MyrbetriqMirabegron215$120,947
OrgovyxRelugolix23$68,850
XgevaDenosumab18$56,461
TestopelTestosterone39$42,905
Tamsulosin Hcl1,235$12,815
NatestoTestosterone14$10,833
Potassium Citrate ErPotassium Citrate106$8,640
Silodosin82$7,842
Finasteride775$7,377
Testosterone61$6,727
CialisTadalafil17$6,179
ToviazFesoterodine Fumarate21$5,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$2,619$1,178,33459 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,445$711,867258 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$1,717$400,642478 claims
AmgenXgeva$187$56,46118 claims
Endo Pharmaceuticals Inc.Testopel$316$42,90539 claims
Acerus Pharmaceuticals CorporationNatesto$288$10,83314 claims
PfizerToviaz$603$5,39221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.

Other urology in Mount Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →